1′-cyano nucleoside analogs and methods for treatment of viral infections
1′-Cyano nucleoside analogs of Formula I and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
1. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated for oral administration.
4. A method for treating a coronavirus infection in a human in need thereof, wherein the method comprises administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the coronavirus infection is a zoonotic cornavirus infection.
6. The method of claim 4 , wherein the coronavirus infection is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
7. The method of claim 4 , wherein the method comprises orally administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
8. The method of claim 4 , wherein the method further comprises administering to the human a therapeutically effective amount of at least one additional therapeutic agent or prophylactic agent.
9. A compound of the following formula:
10. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and the compound of claim 9 .
11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is formulated for oral administration.
12. A method for treating a coronavirus infection in a human in need thereof, wherein the method comprises administering to the human a therapeutically effective amount of the compound of claim 9 .
13. The method of claim 12 , wherein the coronavirus infection is a zoonotic coronavirus infection.
14. The method of claim 12 , wherein the coronavirus infection is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
15. The method of claim 12 , wherein the method comprises orally administering to the human a therapeutically effective amount of the compound of claim 9 .
16. The method of claim 12 , wherein the method further comprises administering to the human a therapeutically effective amount of at least one additional therapeutic agent or prophylactic agent.